[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369122-105":59,"doc-detail-369122-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancements-in-gene-therapies-targeting-mutant-kras-in-cancers","Advancements in gene therapies targeting mutant KRAS in cancers","","KRAS gene mutations are established tumourigenic drivers in colorectal, pancreatic, and lung cancers, promoting uncontrolled proliferation and altering the tumour microenvironment early in carcinogenesis. Despite advances in KRAS inhibitor development, clinical use remains restricted to specific KRAS-mutant cancer types and can cause moderate to serious side effects. This review evaluates strategies for more universal KRAS-targeted therapeutics, including gene therapy options such as siRNA, miRNA, and CRISPR, and lipid-based nanocarriers for delivering gene cargos, and outlines future directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancements-in-gene-therapies-targeting-mutant-kras-in-cancers/369122/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancements-in-gene-therapies-targeting-mutant-kras-in-cancers/369122.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are KRAS mutations important in cancer development?","Question",{"text":112,"@type":113},"KRAS mutations are tumourigenic drivers that promote uncontrolled cell proliferation and alter the tumour microenvironment during early carcinoma stages.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations affect current KRAS inhibitor therapies?",{"text":117,"@type":113},"Their clinical application is limited to particular cancer types carrying relevant KRAS mutations, and they can induce moderate to serious side effects.",{"name":119,"@type":110,"acceptedAnswer":120},"Which gene therapy and delivery approaches are discussed for targeting KRAS mutants?",{"text":121,"@type":113},"The review explores gene therapy strategies including siRNA, miRNA, and CRISPR, and discusses using lipid-based nanocarriers to deliver gene cargos targeting KRAS gene mutants.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369122,1790670060,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Cancer and Metastasis Reviews (2025) 44:24  \n[https://doi.org/10.1007/s10555-025-10243-9](https://doi.org/10.1007/s10555-025-10243-9)  \nAdvancements in gene therapies targeting mutant KRAS in cancers  \nYuhang Wang1 · Thuy Anh Bui1,2,3 · Xinpu Yang1 · Gyorgy Hutvagner1 · Wei Deng1,4  \nReceived: 10 September 2024 / Accepted: 8 January 2025 / Published online: 17 January 2025 © The Author(s) 2025  \nAbstract  \nMutations in the KRAS gene are well-known tumourigenic drivers of colorectal, pancreatic and lung cancers. Mechanistically, these mutations promote uncontrolled cell proliferation and alter the tumour microenvironment during early carcinoma stages. Given their critical carcinogenic functions, significant progress has been made in developing KRAS inhibitors for cancer treatment. However, clinical applications of these KRAS inhibitor compounds are limited to specific cancer types which carry the relevant KRAS mutations. Additionally, clinical findings have shown that these compounds can induce moderate to serious side effects. Therefore, new approaches have emerged focusing on the development of universal therapeutics capable of targeting a wider range of KRAS mutations, minimising toxicity and enhancing the therapeutic efficacy. This review aims to examine these therapeutic strategies in the context of cancer treatment. It firstly provides an overview of fundamental KRAS biology within the cell signalling landscape and how KRAS mutations are associated with cancer pathogenesis. Subsequently, it introduces the development of current KRAS inhibitors which target certain KRAS mutants in different types of cancer. It then explores the potential of gene therapy approaches, including siRNA, miRNA and CRISPR methodologies. Furthermore, it discusses the use of lipid-based nanocarriers to deliver gene cargos for targeting KRAS gene mutants. Finally, it provides the insights into the future prospects for combatting KRAS mutation-associated cancers.  \nGraphical Abstract  \nKeywords KRAS mutation; Cancer treatment · Gene therapy · Inhibitor; Lipid nanocarrier  \nYuhang Wang and Thuy Anh Bui contributed equally to this work.  \nExtended author information available on the last page of the article  \n1 Structure and function of KRAS  \nThe KRAS gene, part ofthe rat sarcoma viral oncogene family, was identified in 1982, along with HRAS and NRAS [1, 2] . This gene is located on chromosome 12 and produce two protein variants, KRAS-4A and KRAS-4B with the latter predominates in cells [3] . At protein level, KRAS acts as a membrane-bound G protein which functions as a binary switch between its inactive GDP-bound and active GTP-bound states to modulate signal transduction from activated membrane receptors to downstream signalling pathways within the target cells [4, 5]. To perform this function, the KRAS polypeptide consists of six beta strands and five alpha helices with specific regions such as P-loop, Switch I and Switch II which regulate KRAS molecular activity and interactions with other cellular components (Fig. 1A) [5]. With its low intrinsic GTPase activity, KRAS relies on GTPase activating proteins (GAPs) like SOS and NF1 to catalyse hydrolysis (Fig. 1B) [6] . Mechanistically, under normal conditions, KRAS remains inactive, bound to GDP [7]. At the presence of growth factors, stimulated cells initiate the substitution of GDP by GTP, thus activating KRASand initiating signalling cascades [8] . After that, GAPs promote KRAS inactivation by enabling GDP binding.  \nKRAS activation requires key components such as GRB2-SOS1, RAS-GRF1 and Src homology phosphatase 2 (SHP2)(Fig. 2) [9] . The GRB2-SOS1 complex plays a crucial role, acting as an intermediary activated by growth factors like epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factors (FGFs) [9]. Upon receptor tyrosine kinase activation, GRB2 binds to phosphorylated receptors and recruits SOS1, a guanine nucleotide exchange factor (GEF) [10] . This ","cbCaih7Pui523iM3","https://ap.wps.com/l/cbCaih7Pui523iM3","pdf",1388762,17,"English","# Abstract\n# Structure and function of KRAS\n## KRAS activation and signalling mechanisms\n## Downstream pathways regulated by KRAS\n# KRAS mutations in cancer pathogenesis","[{\"question\":\"Why are KRAS mutations important in cancer development?\",\"answer\":\"KRAS mutations are tumourigenic drivers that promote uncontrolled cell proliferation and alter the tumour microenvironment during early carcinoma stages.\"},{\"question\":\"What limitations affect current KRAS inhibitor therapies?\",\"answer\":\"Their clinical application is limited to particular cancer types carrying relevant KRAS mutations, and they can induce moderate to serious side effects.\"},{\"question\":\"Which gene therapy and delivery approaches are discussed for targeting KRAS mutants?\",\"answer\":\"The review explores gene therapy strategies including siRNA, miRNA, and CRISPR, and discusses using lipid-based nanocarriers to deliver gene cargos targeting KRAS gene mutants.\"}]","Advancements in gene therapies targeting mutant KRAS in cancers | PDF",1790180860,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/131f99e6508e8a4748c66fd1dccfded1.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d4c41402ff1cc551bbafe87c0513169.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11159d8729f5f06cefb7a0a56dcf6774.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49961d3ae71f383eedd834fae7162249.webp",980,1301]